Kleileuk

Bendamustine Hydrochloride, the active ingredient in Kleileuk, is an alkylating agent presented as an injection solution for intravenous use. It is employed in the treatment of chronic lymphocytic leukemia and non‑Hodgkin lymphoma in adult patients.

GNH USA supplies Kleileuk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality, traceability and compliance with cold‑chain requirements for injectable medicines. Clients receive technical support and regulatory documentation for seamless import.

Bendamustine Hydrochloride is an alkylating antineoplastic agent used in hematologic malignancies.

- Chronic lymphocytic leukemia: improves remission rates and disease control. - Non‑Hodgkin lymphoma: induces tumor regression and prolongs progression‑free survival. - Relapsed or refractory non‑Hodgkin lymphoma: provides a therapeutic option after prior therapy.

Adverse reactions may occur with intravenous administration of bendamustine.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness during treatment cycles. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels that may cause bruising.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections requiring prompt treatment. - Pulmonary toxicity: interstitial pneumonitis or respiratory distress. - Secondary malignancies: emergence of new cancers after therapy.

Prior to initiating therapy, several safety considerations are recommended.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess infection risk: screen for active infections before treatment. - Evaluate renal and hepatic function: adjust therapy if organ impairment is present. - Avoid live vaccines: immunization with live agents may cause disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent strong CYP3A4 inhibitors: may increase bendamustine exposure. - Co‑administration with live vaccines: heightened risk of infection. - Combination with other myelosuppressive chemotherapy: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may modestly raise drug levels. - Use with G‑CSF agents: may reduce duration of neutropenia. - Concomitant anticoagulants: monitor for increased bleeding tendency.